| Abstrakt: |
This article provides information on a clinical trial, NCT06489704, that is currently underway in Kyrgyzstan. The trial aims to study the effect of relocating high altitude residents with high altitude pulmonary hypertension (HAPH) from 3200 m to 760 m on pulmonary artery pressure (PAP). The study will use echocardiography and arterial blood gases to assess various outcomes, including changes in PAP, cardiac output, and tricuspid pressure gradient. The trial is still in the recruitment phase and is expected to be completed by December 2024. The study is led by Prof. Dr. Talant M Sooronbaev and Prof. Dr. Silvia Ulrich. [Extracted from the article] |
